Latest & greatest articles for hydroxychloroquine

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on hydroxychloroquine or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on hydroxychloroquine and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for hydroxychloroquine

1. Covid-19: More about chloroquine and hydroxychloroquine

Covid-19: More about chloroquine and hydroxychloroquine More about chloroquine and hydroxychloroquine - CEBM CEBM The Centre for Evidence-Based Medicine develops, promotes and disseminates better evidence for healthcare. Navigate this website More about chloroquine and hydroxychloroquine May 30, 2020 Jeffrey K Aronson, Robin E Ferner* On behalf of the Oxford COVID-19 Evidence Service Team Centre for Evidence-Based Medicine, Nuffield Department of Primary Care Health Sciences University (...) of Oxford *University of Birmingham Correspondence to VERDICT The hypothesis that the 4-aminoquinolines chloroquine and hydroxychloroquine may be beneficial in the treatment of COVID-19 is a weak one, based on poor mechanistic reasoning and inconsistent results of studies in vitro, in laboratory animals, and in humans. It is likely that even if chloroquine and hydroxychloroquine are effective in COVID-19, the beneficial effects will be small. The risks of adverse reactions to these drugs may

2020 Oxford COVID-19 Evidence Service

2. Safety of hydroxychloroquine in COVID-19 and other diseases: a systematic review and meta-analysis of 53 randomized trials Full Text available with Trip Pro

Safety of hydroxychloroquine in COVID-19 and other diseases: a systematic review and meta-analysis of 53 randomized trials Safety of hydroxychloroquine in COVID-19 and other diseases: a systematic review and meta-analysis of 53 randomized trials - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced features are temporarily unavailable. COVID-19 is an emerging, rapidly (...) . Safety of hydroxychloroquine in COVID-19 and other diseases: a systematic review and meta-analysis of 53 randomized trials , , , , , , , Affiliations Expand Affiliations 1 Department of Pharmacy, Zhongshan Hospital, Fudan University, Shanghai, 200032, China. 2 Department of Rheumatology, Zhongshan Hospital, Fudan University, Shanghai, 200032, China. 3 Department of Pharmacy, Zhongshan Hospital, Fudan University, Shanghai, 200032, China. li.xiaoyu@zs-hospital.sh.cn. 4 Department of Pharmacy, Zhongshan

2020 EvidenceUpdates

3. Update I. A systematic review on the efficacy and safety of chloroquine/hydroxychloroquine for COVID-19 Full Text available with Trip Pro

Update I. A systematic review on the efficacy and safety of chloroquine/hydroxychloroquine for COVID-19 Update I. A systematic review on the efficacy and safety of chloroquine/hydroxychloroquine for COVID-19 - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced features are temporarily unavailable. COVID-19 is an emerging, rapidly evolving situation. Get the latest public (...) new results Optional text in email: Save Cancel Create a file for external citation management software Create file Cancel Your RSS Feed Name of RSS Feed: Number of items displayed: Create RSS Cancel RSS Link Copy Actions Cite Share Permalink Copy Page navigation Review J Crit Care Actions . 2020 Jul 11;59:176-190. doi: 10.1016/j.jcrc.2020.06.019. Online ahead of print. Update I. A systematic review on the efficacy and safety of chloroquine/hydroxychloroquine for COVID-19 , , , , , Affiliations

2020 EvidenceUpdates

4. QT prolongation, torsades de pointes, and sudden death with short courses of chloroquine or hydroxychloroquine as used in COVID-19: A systematic review Full Text available with Trip Pro

QT prolongation, torsades de pointes, and sudden death with short courses of chloroquine or hydroxychloroquine as used in COVID-19: A systematic review QT prolongation, torsades de pointes, and sudden death with short courses of chloroquine or hydroxychloroquine as used in COVID-19: A systematic review - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced features (...) pointes, and sudden death with short courses of chloroquine or hydroxychloroquine as used in COVID-19: A systematic review , , , , Affiliations Expand Affiliations 1 NYU Langone Health, NYU School of Medicine, New York, New York. Electronic address: Lior.Jankelson@nyulangone.org. 2 Dalhousie University, College of Pharmacy, Halifax, Nova Scotia, Canada. Electronic address: Giorgio.Karam@dal.ca. 3 Pharmacy Foundation of Haarlem Hospitals, Haarlem, The Netherlands; Spaarne Gasthuis, Haarlem

2020 EvidenceUpdates

5. Hydroxychloroquine in covid-19: no proven efficacy, including in less severe forms of the disease

Hydroxychloroquine in covid-19: no proven efficacy, including in less severe forms of the disease Prescrire IN ENGLISH - Spotlight ''Hydroxychloroquine in covid-19: no proven efficacy, including in less severe forms of the disease'', 24 July 2020 {1} {1} {1} | | > > > Hydroxychloroquine in covid-19: no proven efficacy, including in less severe forms of the disease Spotlight Every month, the subjects in Prescrire’s Spotlight. 100 most recent :  |   |   |   |  (...)  |   |   |   |   |  Spotlight Hydroxychloroquine in covid-19: no proven efficacy, including in less severe forms of the disease NEWS UPDATE The detailed results of four comparative trials of hydroxychloroquine in patients with covid-19 were released in late July 2020: two trials in patients hospitalised for covid-19, and two others in patients who were not hospitalised and had milder forms of the disease. As of June 2020, hydroxychloroquine (Plaquenil°) had

2020 Prescrire

6. COVID-19: Treatment with Hydroxychloroquine (HCQ)

COVID-19: Treatment with Hydroxychloroquine (HCQ) COVID-19: TREATMENT WITH HYDROXYCHLOROQUINE (HCQ) A Rapid Guidance Summary from the Penn Medicine Center for Evidence-based Practice Last updated June 26, 2020. All links rechecked June 26 unless otherwise noted. This Rapid Guidance Summary is a description of existing guidance and evidence reviews from a variety of sources that was in effect at the time of publication. It should not be used or interpreted as a clinical practice guideline (...) , but instead can be used in development of local recommendations and policies. Key questions answered in this summary • Is hydroxychloroquine safe and effective for treatment of COVID-19 disease? Use of hydroxychloroquine for prevention of COVID-19 disease is outside the scope of this report. Summary of major recommendations • The FDA has withdrawn Emergency Use Authorization for hydroxychloroquine in COVID-19 disease, but clinical trials remain in progress. • Systematic reviews of clinical evidence show

2020 Centre for Evidence-Based Practice, Penn Medicine

7. COVID-19: Prophylactic Use of Hydroxychloroquine (HCQ)

COVID-19: Prophylactic Use of Hydroxychloroquine (HCQ) COVID-19: PROPHYLACTIC USE OF HYDROXYCHLOROQUINE (HCQ) A Rapid Guidance Summary from the Penn Medicine Center for Evidence-based Practice Last updated July 1, 2020. All links rechecked June 30 unless otherwise noted. This Rapid Guidance Summary is a description of existing guidance and evidence reviews from a variety of sources that was in effect at the time of publication. It should not be used or interpreted as a clinical practice (...) guideline, but instead can be used in development of local recommendations and policies. Key questions answered in this summary • Is hydroxychloroquine effective for prevention of clinical disease in patients who have been exposed to SARS-CoV-2? Use of hydroxychloroquine for treatment of confirmed COVID-19 disease is outside the scope of this report. Summary of major recommendations • Use of hydroxychloroquine or chloroquine for prevention of COVID-19 disease is not recommended outside of approved

2020 Centre for Evidence-Based Practice, Penn Medicine

8. Should Clinicians Use Chloroquine or Hydroxychloroquine Alone or in Combination With Azithromycin for the Prophylaxis or Treatment of COVID-19? Living Practice Points From the American College of Physicians Full Text available with Trip Pro

Should Clinicians Use Chloroquine or Hydroxychloroquine Alone or in Combination With Azithromycin for the Prophylaxis or Treatment of COVID-19? Living Practice Points From the American College of Physicians Update Alert: Should Clinicians Use Chloroquine or Hydroxychloroquine Alone or in Combination With Azithromycin for the Prophylaxis or Treatment of COVID-19? Living Practice Points From the American College of Physicians | Annals of Internal Medicine LOGIN TO YOUR ACCOUNT or Create a new (...) , Worcester, Massachusetts (G.M.A.) , Portland Veterans Affairs Medical Center, Portland, Oregon (A.J.O.) , University of Pennsylvania, Philadelphia, Pennsylvania (M.A.F.) , University of Illinois College of Medicine, Urbana, Illinois (J.A.J.) , Oregon Health & Science University, Portland, Oregon (L.L.H.) , In this letter, we update the American College of Physicians' previous practice points about chloroquine or hydroxychloroquine alone or in combination with azithromycin for prophylaxis or treatment

2020 American College of Physicians

9. Does Adding of Hydroxychloroquine to the Standard Care Provide any Benefit in Reducing the Mortality among COVID-19 Patients?: a Systematic Review Full Text available with Trip Pro

Does Adding of Hydroxychloroquine to the Standard Care Provide any Benefit in Reducing the Mortality among COVID-19 Patients?: a Systematic Review Does Adding of Hydroxychloroquine to the Standard Care Provide any Benefit in Reducing the Mortality among COVID-19 Patients?: a Systematic Review - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced features are temporarily (...) file Cancel Your RSS Feed Name of RSS Feed: Number of items displayed: Create RSS Cancel RSS Link Copy Actions Cite Share Permalink Copy Page navigation Review J Neuroimmune Pharmacol Actions . 2020 Jun 9;1-9. doi: 10.1007/s11481-020-09930-x. Online ahead of print. Does Adding of Hydroxychloroquine to the Standard Care Provide any Benefit in Reducing the Mortality among COVID-19 Patients?: a Systematic Review , , , , Affiliations Expand Affiliations 1 Department of Pharmacology, All India Institute

2020 EvidenceUpdates

10. Observational Study of Hydroxychloroquine in Hospitalized Patients with Covid-19. Full Text available with Trip Pro

Observational Study of Hydroxychloroquine in Hospitalized Patients with Covid-19. Hydroxychloroquine has been widely administered to patients with Covid-19 without robust evidence supporting its use.We examined the association between hydroxychloroquine use and intubation or death at a large medical center in New York City. Data were obtained regarding consecutive patients hospitalized with Covid-19, excluding those who were intubated, died, or discharged within 24 hours after presentation (...) to the emergency department (study baseline). The primary end point was a composite of intubation or death in a time-to-event analysis. We compared outcomes in patients who received hydroxychloroquine with those in patients who did not, using a multivariable Cox model with inverse probability weighting according to the propensity score.Of 1446 consecutive patients, 70 patients were intubated, died, or discharged within 24 hours after presentation and were excluded from the analysis. Of the remaining 1376

2020 NEJM

11. A Randomized Trial of Hydroxychloroquine as Postexposure Prophylaxis for Covid-19. Full Text available with Trip Pro

A Randomized Trial of Hydroxychloroquine as Postexposure Prophylaxis for Covid-19. Coronavirus disease 2019 (Covid-19) occurs after exposure to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). For persons who are exposed, the standard of care is observation and quarantine. Whether hydroxychloroquine can prevent symptomatic infection after SARS-CoV-2 exposure is unknown.We conducted a randomized, double-blind, placebo-controlled trial across the United States and parts of Canada (...) testing hydroxychloroquine as postexposure prophylaxis. We enrolled adults who had household or occupational exposure to someone with confirmed Covid-19 at a distance of less than 6 ft for more than 10 minutes while wearing neither a face mask nor an eye shield (high-risk exposure) or while wearing a face mask but no eye shield (moderate-risk exposure). Within 4 days after exposure, we randomly assigned participants to receive either placebo or hydroxychloroquine (800 mg once, followed by 600 mg in 6

2020 NEJM

12. COVID-19: Treatment with Hydroxychloroquine (HCQ)

COVID-19: Treatment with Hydroxychloroquine (HCQ) COVID-19: TREATMENT WITH HYDROXYCHLOROQUINE (HCQ) A Rapid Guidance Summary from the Penn Medicine Center for Evidence-based Practice Last updated May 18, 2020 3:00 pm All links rechecked May 17 unless otherwise noted. This Rapid Guidance Summary is a description of existing guidance and evidence reviews from a variety of sources that was in effect at the time of publication. It should not be used or interpreted as a clinical practice guideline (...) , but instead can be used in development of local recommendations and policies. Key questions answered in this summary • Is hydroxychloroquine safe and effective for treatment of COVID-19 disease? Use of hydroxychloroquine for prevention of COVID-19 disease is outside the scope of this report. Summary of major recommendations • Use of hydroxychloroquine and chloroquine for treatment of COVID-19 disease is considered an off-label indication. Clinical trials are in progress. • Current clinical evidence

2020 Centre for Evidence-Based Practice, Penn Medicine

13. A Rapid Systematic Review of Clinical Trials Utilizing Chloroquine and Hydroxychloroquine as a Treatment for COVID-19 Full Text available with Trip Pro

A Rapid Systematic Review of Clinical Trials Utilizing Chloroquine and Hydroxychloroquine as a Treatment for COVID-19 A Rapid Systematic Review of Clinical Trials Utilizing Chloroquine and Hydroxychloroquine as a Treatment for COVID-19 - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced features are temporarily unavailable. National Institutes of Health National Library (...) displayed: Create RSS Cancel RSS Link Copy Actions Cite Share Permalink Copy Page navigation Acad Emerg Med Actions . 2020 Jun;27(6):493-504. doi: 10.1111/acem.14005. Epub 2020 May 29. A Rapid Systematic Review of Clinical Trials Utilizing Chloroquine and Hydroxychloroquine as a Treatment for COVID-19 , , Affiliations Expand Affiliations 1 From the, SUNY Downstate Medical Center, Brooklyn, NY. 2 Department of Emergency Medicine, SUNY Downstate Medical Center, Brooklyn, NY. PMID: 32359203 PMCID: DOI

2020 EvidenceUpdates

14. Hydroxychloroquine in patients with COVID-19: A Systematic Review and meta-analysis Full Text available with Trip Pro

Hydroxychloroquine in patients with COVID-19: A Systematic Review and meta-analysis "Hydroxychloroquine in Patients With COVID-19: A Systematic Review and Meta-Analysis." - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced features are temporarily unavailable. National Institutes of Health National Library of Medicine National Center for Biotechnology Information Show (...) Permalink Copy Page navigation Diabetes Metab Syndr Actions . 2020 May 12;14(4):589-596. doi: 10.1016/j.dsx.2020.05.017. Online ahead of print. "Hydroxychloroquine in Patients With COVID-19: A Systematic Review and Meta-Analysis." , , , Affiliations Expand Affiliations 1 Diabetes & Endocrinology, G.D Hospital & Diabetes Institute, Kolkata, West Bengal, India. Electronic address: draksingh_2001@yahoo.com. 2 College of Medicine and JNM Hospital, Kalyani, Nadia, West Bengal, India. 3 Gynaecology

2020 EvidenceUpdates

15. An Updated Systematic Review of the Therapeutic Role of Hydroxychloroquine in Coronavirus Disease-19 (COVID-19) Full Text available with Trip Pro

An Updated Systematic Review of the Therapeutic Role of Hydroxychloroquine in Coronavirus Disease-19 (COVID-19) An Updated Systematic Review of the Therapeutic Role of Hydroxychloroquine in Coronavirus Disease-19 (COVID-19) - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced features are temporarily unavailable. National Institutes of Health National Library of Medicine (...) displayed: Create RSS Cancel RSS Link Copy Actions Cite Share Permalink Copy Page navigation Review Clin Drug Investig Actions . 2020 Jul;40(7):591-601. doi: 10.1007/s40261-020-00927-1. An Updated Systematic Review of the Therapeutic Role of Hydroxychloroquine in Coronavirus Disease-19 (COVID-19) , , , Affiliations Expand Affiliations 1 Department of Clinical Pharmacology, Jawaharlal Institute of Postgraduate Medical Education and Research, Puducherry, 605 006, India. 2 Department of Pharmacology, KPC

2020 EvidenceUpdates

16. Hydroxychloroquine or Chloroquine for Treatment or Prophylaxis of COVID-19: A Living Systematic Review. (Abstract)

Hydroxychloroquine or Chloroquine for Treatment or Prophylaxis of COVID-19: A Living Systematic Review. Hydroxychloroquine and chloroquine have antiviral effects in vitro against severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2).To summarize evidence about the benefits and harms of hydroxychloroquine or chloroquine for the treatment or prophylaxis of coronavirus disease 2019 (COVID-19).PubMed (via MEDLINE), EMBASE (via Ovid), Scopus, Web of Science, Cochrane Library, bioRxiv (...) , Preprints, ClinicalTrials.gov, World Health Organization International Clinical Trials Registry Platform, and the Chinese Clinical Trials Registry from 1 December 2019 until 8 May 2020.Studies in any language reporting efficacy or safety outcomes from hydroxychloroquine or chloroquine use in any setting in adults or children with suspected COVID-19 or at risk for SARS-CoV-2 infection.Independent, dually performed data extraction and quality assessments.Four randomized controlled trials, 10 cohort

2020 Annals of Internal Medicine

17. RETRACTED: Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis. Full Text available with Trip Pro

RETRACTED: Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis. Hydroxychloroquine or chloroquine, often in combination with a second-generation macrolide, are being widely used for treatment of COVID-19, despite no conclusive evidence of their benefit. Although generally safe when used for approved indications such as autoimmune disease or malaria, the safety and benefit of these treatment regimens are poorly evaluated (...) in COVID-19.We did a multinational registry analysis of the use of hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19. The registry comprised data from 671 hospitals in six continents. We included patients hospitalised between Dec 20, 2019, and April 14, 2020, with a positive laboratory finding for SARS-CoV-2. Patients who received one of the treatments of interest within 48 h of diagnosis were included in one of four treatment groups (chloroquine alone, chloroquine

2020 Lancet

18. Web Exclusive. Annals Consult Guys - Hydroxychloroquine: Update on an Old Drug. (Abstract)

Web Exclusive. Annals Consult Guys - Hydroxychloroquine: Update on an Old Drug. [Figure: see text].

2020 Annals of Internal Medicine

19. Clinical efficacy of hydroxychloroquine in patients with covid-19 pneumonia who require oxygen: observational comparative study using routine care data. Full Text available with Trip Pro

Clinical efficacy of hydroxychloroquine in patients with covid-19 pneumonia who require oxygen: observational comparative study using routine care data. To assess the effectiveness of hydroxychloroquine in patients admitted to hospital with coronavirus disease 2019 (covid-19) pneumonia who require oxygen.Comparative observational study using data collected from routine care.Four French tertiary care centres providing care to patients with covid-19 pneumonia between 12 March and 31 March (...) 2020.181 patients aged 18-80 years with documented severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pneumonia who required oxygen but not intensive care.Hydroxychloroquine at a dose of 600 mg/day within 48 hours of admission to hospital (treatment group) versus standard care without hydroxychloroquine (control group).The primary outcome was survival without transfer to the intensive care unit at day 21. Secondary outcomes were overall survival, survival without acute respiratory distress

2020 BMJ

20. Hydroxychloroquine in patients with mainly mild to moderate coronavirus disease 2019: open label, randomised controlled trial. Full Text available with Trip Pro

Hydroxychloroquine in patients with mainly mild to moderate coronavirus disease 2019: open label, randomised controlled trial. To assess the efficacy and safety of hydroxychloroquine plus standard of care compared with standard of care alone in adults with coronavirus disease 2019 (covid-19).Multicentre, open label, randomised controlled trial.16 government designated covid-19 treatment centres in China, 11 to 29 February 2020.150 patients admitted to hospital with laboratory confirmed covid-19 (...) were included in the intention to treat analysis (75 patients assigned to hydroxychloroquine plus standard of care, 75 to standard of care alone).Hydroxychloroquine administrated at a loading dose of 1200 mg daily for three days followed by a maintenance dose of 800 mg daily (total treatment duration: two or three weeks for patients with mild to moderate or severe disease, respectively).Negative conversion of severe acute respiratory syndrome coronavirus 2 by 28 days, analysed according

2020 BMJ